3月19日 - ** 生物技术公司Humacyte的HUMA.O股价盘前下跌10.1%至0.95美元
** 总部位于北卡罗来纳州达勒姆的HUMA公司与几家新的机构投资者达成协议 (link) 以注册直接发行的方式出售2,500万股股票，募集资金总额为2,000万美元。
** 由一家新的生命科学专用投资者和一家长线共同基金--HUMA--牵头发行
** 隐含发行价为每股 0.80 美元，较股票上次收盘价上涨 24.5%
** 募集资金将用于资助其用于血管创伤患者的植入物 Symvess 的商业化及其他用途
** 泰坦合伙公司是此次发行的独家配售代理
** 7家券商中有6家给予该股 "买入 "或更高评级，1家给予 "持有 "评级；PT中位数为3.50美元--数据由LSEG编制
** 截至上次收盘，HUMA股价年累计上涨10.4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.